Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer

J Med Chem. 2022 Jan 13;65(1):785-810. doi: 10.1021/acs.jmedchem.1c01864. Epub 2021 Dec 28.

Abstract

CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Herein, we report the structural optimization of a series of 1-(indolizin-3-yl)ethan-1-one compounds as new selective CBP bromodomain inhibitors, aiming to improve cellular potency and metabolic stability. This process led to compound 9g (Y08284), which possesses good liver microsomal stability and pharmacokinetic properties (F = 25.9%). Furthermore, the compound is able to inhibit CBP bromodomain as well as the proliferation, colony formation, and migration of prostate cancer cells. Additionally, the new inhibitor shows promising antitumor efficacy in a 22Rv1 xenograft model (TGI = 88%). This study provides new lead compounds for further development of drugs for the treatment of prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • CREB-Binding Protein / antagonists & inhibitors*
  • Caco-2 Cells
  • Cell Line, Tumor
  • Drug Design
  • Humans
  • Indolizidines / chemical synthesis*
  • Indolizidines / pharmacokinetics
  • Indolizidines / pharmacology
  • Male
  • Mice
  • Mice, SCID
  • Microsomes, Liver
  • Models, Molecular
  • Molecular Docking Simulation
  • Prostatic Neoplasms / drug therapy*
  • Rats
  • Rats, Sprague-Dawley
  • Structure-Activity Relationship
  • Tumor Stem Cell Assay
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Indolizidines
  • CREB-Binding Protein